FITABREVO Trademark

Trademark Overview

On Wednesday, June 16, 2021, a trademark application was filed for FITABREVO with the United States Patent and Trademark Office. The USPTO has given the FITABREVO trademark a serial number of 90777889. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Thursday, May 2, 2024. This trademark is owned by Genzyme Corporation. The FITABREVO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of hemophilia
fitabrevo

General Information

Serial Number90777889
Word MarkFITABREVO
Filing DateWednesday, June 16, 2021
Status733 - FOURTH EXTENSION - GRANTED
Status DateThursday, May 2, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 19, 2022

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of hemophilia

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, September 2, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGenzyme Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02141
Party NameGenzyme Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02142

Trademark Events

Event DateEvent Description
Thursday, September 9, 2021ASSIGNED TO LIE
Saturday, June 19, 2021NEW APPLICATION ENTERED
Friday, June 25, 2021TEAS VOLUNTARY AMENDMENT RECEIVED
Thursday, September 2, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, March 14, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, September 9, 2021PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Monday, March 7, 2022ASSIGNED TO EXAMINER
Wednesday, March 30, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 19, 2022PUBLISHED FOR OPPOSITION
Tuesday, November 8, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, April 19, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 14, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, November 10, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 11, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, November 8, 2022SOU EXTENSION 1 FILED
Tuesday, November 8, 2022SOU EXTENSION 1 GRANTED
Tuesday, May 9, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, May 9, 2023SOU EXTENSION 2 FILED
Tuesday, May 9, 2023SOU EXTENSION 2 GRANTED
Thursday, May 2, 2024SOU EXTENSION 4 GRANTED
Thursday, May 2, 2024SOU TEAS EXTENSION RECEIVED
Thursday, May 2, 2024SOU EXTENSION 4 FILED
Friday, May 3, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, October 25, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, October 23, 2023SOU TEAS EXTENSION RECEIVED
Monday, October 23, 2023SOU EXTENSION 3 FILED
Monday, October 23, 2023SOU EXTENSION 3 GRANTED

Related Keywords

fitabrevo hemophilia treatment preparations pharmaceutical